Open an account

iBio

IBIO · NYSE American

$0.821+$0.0609 (+8.01%)TodayMarket closed ·
Prev close $0.7601

About IBIO

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. The company has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.

Employees
20
Headquarters
San Diego, California
Listed
Aug 18, 2008
Sector
Health Care
Industry
Biotechnology
Website
ibioinc.com

IBIO key statistics

Market cap
49.96M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
839.66K
Volume
2.22M
Open price
$0.7601
High today
$0.8914
Low today
$0.7601
52 Week high
$3.82
52 Week low
$0.7328

iBio (IBIO) at a glance

iBio (IBIO) last traded at $0.821, with a market cap of 49.96M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7601 and $0.8914. The current price is 8.0% above the day's low and 7.9% below its high.

Volume so far is 2.22M shares, above the average of 839.66K shares a day.

Over the past year iBio has ranged from $0.7328 to $3.82, and now sits 3% of the way up that range.

iBio met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q4 FY26 it reported -$0.07 per share against an estimate of -$0.065.

The average analyst price target is $5.80, 606.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $5.80
Low
$4.24
Now
$0.821
High
$7.35

IBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 6.1% on average.

  1. Q1 FY25: reported -$0.46 per share against an estimate of -$0.4896
  2. Q2 FY25: reported -$0.48 per share against an estimate of -$0.4692
  3. Q3 FY25: reported -$0.49 per share against an estimate of -$0.3264
  4. Q4 FY25: reported -$0.49 per share against an estimate of -$0.3723
  5. Q1 FY26: reported -$0.11 per share against an estimate of -$0.1046
  6. Q2 FY26: reported -$0.09 per share against an estimate of -$0.0842
  7. Q3 FY26: reported -$0.06 per share against an estimate of -$0.0639
  8. Q4 FY26: reported -$0.07 per share against an estimate of -$0.065

IBIO news

  • Press releaseGlobe Newswire

    iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  • Press releaseGlobe Newswire

    iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Avi Kapoor

    US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

  • Press releaseGlobe Newswire

    iBio Announces Closing of $50 Million Public Offering

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as iBio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.